Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more
Pharmaron Beijing Co., Ltd. (PHBBF) - Net Assets
Latest net assets as of June 2025: $14.87 Billion USD
Based on the latest financial reports, Pharmaron Beijing Co., Ltd. (PHBBF) has net assets worth $14.87 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.20 Billion) and total liabilities ($10.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.87 Billion |
| % of Total Assets | 59.01% |
| Annual Growth Rate | 12.33% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.67 |
Pharmaron Beijing Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how Pharmaron Beijing Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmaron Beijing Co., Ltd. (2020–2024)
The table below shows the annual net assets of Pharmaron Beijing Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.22 Billion | +7.44% |
| 2023-12-31 | $13.24 Billion | +22.12% |
| 2022-12-31 | $10.84 Billion | +5.29% |
| 2021-12-31 | $10.30 Billion | +15.24% |
| 2020-12-31 | $8.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmaron Beijing Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 234.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.44 Billion | 47.31% |
| Other Components | $7.18 Billion | 52.69% |
| Total Equity | $13.62 Billion | 100.00% |
Pharmaron Beijing Co., Ltd. Competitors by Market Cap
The table below lists competitors of Pharmaron Beijing Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DTZNY
OTCQB:DTZNY
|
$2.34 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
$2.34 Billion |
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
$2.34 Billion |
|
Parq Arauco
SN:PARAUCO
|
$2.35 Billion |
|
DSFIY
PINK:DSFIY
|
$2.34 Billion |
|
Premium Brands Holdings Corporation
PINK:PRBZF
|
$2.34 Billion |
|
Aurubis AG
PINK:AIAGF
|
$2.34 Billion |
|
Spark New Zealand Ltd
PINK:NZTCF
|
$2.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmaron Beijing Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,556,797,361 to 13,619,333,910, a change of 1,062,536,549 (8.5%).
- Net income of 1,793,350,814 contributed positively to equity growth.
- Dividend payments of 542,234,339 reduced retained earnings.
- Other factors decreased equity by 188,579,927.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.79 Billion | +13.17% |
| Dividends Paid | $542.23 Million | -3.98% |
| Other Changes | $-188.58 Million | -1.38% |
| Total Change | $- | 8.46% |
Book Value vs Market Value Analysis
This analysis compares Pharmaron Beijing Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.39x to 0.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $4.96 | $1.93 | x |
| 2021-12-31 | $5.67 | $1.93 | x |
| 2022-12-31 | $5.90 | $1.93 | x |
| 2023-12-31 | $7.03 | $1.93 | x |
| 2024-12-31 | $7.66 | $1.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmaron Beijing Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.17%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.61%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.76x
- Recent ROE (13.17%) is below the historical average (13.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 13.22% | 22.84% | 0.43x | 1.34x | $285.35 Million |
| 2021 | 16.40% | 22.31% | 0.40x | 1.82x | $648.10 Million |
| 2022 | 13.03% | 13.39% | 0.50x | 1.94x | $319.74 Million |
| 2023 | 12.75% | 13.88% | 0.44x | 2.11x | $345.42 Million |
| 2024 | 13.17% | 14.61% | 0.51x | 1.76x | $431.42 Million |
Industry Comparison
This section compares Pharmaron Beijing Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmaron Beijing Co., Ltd. (PHBBF) | $14.87 Billion | 13.22% | 0.69x | $2.34 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |